NeoGenomics, Inc. (NEO) Revenue History
Annual and quarterly revenue from 2000 to present
NEO Revenue Over Time (2000–2025)
NEO Revenue Growth History
23 of 25 years with positive growth- FY2000 revenue growth
- N/A
- FY2001 revenue growth
- -99.6%
- FY2002 revenue growth
- +9249.1%
- FY2003 revenue growth
- +295.7%
- FY2004 revenue growth
- +50.8%
- FY2005 revenue growth
- +237.8%
- FY2006 revenue growth
- +243.6%
- FY2007 revenue growth
- +77.7%
- FY2008 revenue growth
- +74.0%
- FY2009 revenue growth
- +47.2%
- FY2010 revenue growth
- +16.6%
- FY2011 revenue growth
- +26.5%
- FY2012 revenue growth
- +37.7%
- FY2013 revenue growth
- +11.0%
- FY2014 revenue growth
- +31.0%
- FY2015 revenue growth
- +14.6%
- FY2016 revenue growth
- +144.6%
- FY2017 revenue growth
- -1.6%
- FY2018 revenue growth
- +15.2%
- FY2019 revenue growth
- +47.7%
- FY2020 revenue growth
- +8.7%
- FY2021 revenue growth
- +9.0%
- FY2022 revenue growth
- +5.2%
- FY2023 revenue growth
- +16.1%
- FY2024 revenue growth
- +11.6%
- FY2025 revenue growth
- +10.1%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $186.7M | +11.1% |
| Q4 2025 | $190.2M | +10.6% |
| Q3 2025 | $187.8M | +11.9% |
| Q2 2025 | $181.3M | +10.2% |
| Q1 2025 | $168.0M | +7.5% |
| Q4 2024 | $172.0M | +10.6% |
| Q3 2024 | $167.8M | +10.4% |
| Q2 2024 | $164.5M | +12.0% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
NEO's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
NEO Revenue Analysis (2000–2025)
Current Revenue & Growth
As of June 13, 2026, NeoGenomics, Inc. (NEO) generated trailing twelve-month (TTM) revenue of $746.0 million, reflecting strong growth of +11.1% year-over-year. The most recent quarter (Q1 2026) recorded $186.7 million in revenue, down 1.8% sequentially.
Historical Growth Trajectory
NEO's 5-year compound annual growth rate (CAGR) stands at +10.4%, indicating consistent double-digit revenue growth. The 3-year CAGR of +12.6% exceeds the 5-year average, indicating an acceleration in the most recent period. NeoGenomics, Inc.'s highest annual revenue of $727.3 million was recorded in 2025, an all-time high.
Revenue by Segment
NEO's revenue is primarily driven by Commercial Insurance (100%). With over half of revenue concentrated in Commercial Insurance, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including SLNO, CDNA (+19.2% YoY), and NTRA (+36.6% YoY) — NEO has underperformed the peer group in revenue growth. Compare NEO vs SLNO →
NEO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 NEOCurrent | $746M | +11.1% | +10.4% | -9.1% | |
 SLNO | $190M | - | - | 7.9% | |
 CDNA | $380M | +19.2% | +14.6% | -5.5% | |
 NTRA | $2.3B | +36.6% | +42.6% | -13.4% | |
 EXAS | $3.2B | +17.7% | +16.8% | -6.4% | |
 LH | $14.0B | +7.3% | -0.0% | 10.9% |
NEO Historical Revenue Data (2000–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $727.3M | +10.1% | $282.5M | 38.8% | $-66,078,999 | -9.1% |
| 2024 | $660.6M | +11.6% | $290.1M | 43.9% | $-92,106,000 | -13.9% |
| 2023 | $591.6M | +16.1% | $244.6M | 41.3% | $-107,736,000 | -18.2% |
| 2022 | $509.7M | +5.2% | $187.9M | 36.9% | $-157,623,000 | -30.9% |
| 2021 | $484.3M | +9.0% | $187.1M | 38.6% | $-118,754,000 | -24.5% |
| 2020 | $444.4M | +8.7% | $185.9M | 41.8% | $-13,992,000 | -3.1% |
| 2019 | $408.8M | +47.7% | $196.8M | 48.1% | $13.0M | 3.2% |
| 2018 | $276.7M | +15.2% | $127.3M | 46.0% | $10.0M | 3.6% |
| 2017 | $240.3M | -1.6% | $102.0M | 42.4% | $2.9M | 1.2% |
| 2016 | $244.1M | +144.6% | $110.4M | 45.2% | $2.6M | 1.1% |
| 2015 | $99.8M | +14.6% | $43.8M | 43.8% | $-5,635,000 | -5.6% |
| 2014 | $87.1M | +31.0% | $40.7M | 46.8% | $2.2M | 2.5% |
| 2013 | $66.5M | +11.0% | $48K | 0.1% | $3.2M | 4.8% |
| 2012 | $59.9M | +37.7% | $26.8M | 44.8% | $1.2M | 2.0% |
| 2011 | $43.5M | +26.5% | $19.4M | 44.7% | $-409,000 | -0.9% |
What if you invested $1,000 in NEO back in 2000?
Total return with dividends reinvested · 26+ years of data
Calculate ReturnsHow much would $100/month in NEO be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs NEO Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationNEO vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowNEO — Frequently Asked Questions
Quick answers to the most common questions about buying NEO stock.
Is NEO's revenue growth accelerating or slowing?
NEO revenue growth is holding steady at +11.1% year-over-year. TTM revenue is $746M. The current growth rate closely tracks the 5-year CAGR of +10.4%, signalling consistent execution.
What is NEO's revenue history from 2000 to 2026?
NeoGenomics, Inc. (NEO) revenue history spans 2000 to 2026. TTM revenue as of 2026 is $746M, growing at +11.1% YoY. The 5-year CAGR is +10.4%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is NEO's long-term revenue growth rate (CAGR)?
NeoGenomics, Inc.'s 5-year revenue CAGR of +10.4% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +11.1% is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for NEO.
Why does NEO's quarterly revenue fluctuate?
NEO quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. NeoGenomics, Inc.'s revenue data from 2000 to 2026 shows full historical quarterly detail on this page.
How is NEO's revenue distributed by segment?
NEO reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does NEO's revenue compare to industry peers?
NeoGenomics, Inc. (NEO) with TTM revenue of $746M and +11.1% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.